A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis

References

• Lessa FC, Winston LG, McDonald LC, Team EIPCdS. Burden of clostridium difficile infection in the United States. N Engl J Med. 2015;372(24):2369–13. doi:10.1056/NEJMoa1408913.
   PubMedGoogle Scholar
• Olsen MA, Young-Xu Y, Stwalley D, Kelly CP, Gerding DN, Saeed MJ, Mahé C, Dubberke ER. The burden of clostridium difficile infection: estimates of the incidence of CDI from U.S. administrative databases. BMC Infect Dis. 2016;16(1):177. doi:10.1186/s12879-016-1501-7.
   PubMedGoogle Scholar
• Mills JP, Rao K, Young VB. Probiotics for prevention of clostridium difficile infection. Curr Opin Gastroenterol. 2018;34(1):3–10. doi:10.1097/MOG.0000000000000410.
   PubMed Web of Science ®Google Scholar
• Dieterle MG, Young VB. Reducing recurrence of C. difficile infection. Cell. 2017;169(3):375. doi:10.1016/j.cell.2017.03.039.
   PubMed Web of Science ®Google Scholar
• Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol. 2008;190(7):2505–2512. doi:10.1128/JB.01765-07.
   PubMed Web of Science ®Google Scholar
• Weingarden AR, Chen C, Zhang N, Graiziger CT, Dosa PI, Steer CJ, Shaughnessy MK, Johnson JR, Sadowsky MJ, Khoruts A, et al. Ursodeoxycholic acid inhibits clostridium difficile spore germination and vegetative growth, and prevents the recurrence of ileal pouchitis associated with the infection. J Clin Gastroenterol. 2016;50(8):624–630. doi:10.1097/MCG.0000000000000427.
   PubMed Web of Science ®Google Scholar
• Abt MC, McKenney PT, Pamer EG. Clostridium difficile colitis: pathogenesis and host defence. Nat Rev Microbiol. 2016;14(10):609–620. doi:10.1038/nrmicro.2016.108.
   PubMed Web of Science ®Google Scholar
• Evans CT, Safdar N. Current trends in the epidemiology and outcomes of clostridium difficile infection. Clin Infect Dis. 2015;60(suppl_2):S66–S71. doi:10.1093/cid/civ140.
   PubMedGoogle Scholar
• Ofosu A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol. 2016;29(2):147–154. doi:10.20524/aog.2016.0006.
   PubMed Web of Science ®Google Scholar
• Nicholson MR, Thomsen IP, Slaughter JC, Creech CB, Edwards KM. Novel risk factors for recurrent clostridium difficile infection in children. J Pediatr Gastroenterol Nutr. 2015;60(1):18–22. doi:10.1097/MPG.0000000000000553.
   PubMed Web of Science ®Google Scholar
• Maziade PJ, Pereira P, Goldstein EJ. A decade of experience in primary prevention of clostridium difficile infection at a community hospital using the probiotic combination lactobacillus acidophilus CL1285, lactobacillus casei LBC80R, and lactobacillus rhamnosus CLR2 (Bio-K+). Clin Infect Dis. 2015;60(Suppl 2):S144–147. doi:10.1093/cid/civ178.
   PubMed Web of Science ®Google Scholar
• Shelby RD, Tengberg N, Conces M, Olson JK, Navarro JB, Bailey MT, Goodman SD, Besner GE. Development of a standardized scoring system to assess a murine model of clostridium difficile colitis. J Invest Surg. 2019;1–9. doi:10.1080/08941939.2019.1571129.
   PubMed Web of Science ®Google Scholar
• Navarro JB, Mashburn-Warren L, Bakaletz LO, Bailey MT, Goodman SD. Enhanced probiotic potential of. Front Microbiol. 2017;8:489.
   PubMed Web of Science ®Google Scholar
• Olson JK, Navarro JB, Allen JM, McCulloh CJ, Mashburn-Warren L, Wang Y, Varaljay VA, Bailey MT, Goodman SD, Besner GE, et al. An enhanced lactobacillus reuteri biofilm formulation that increases protection against experimental necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol. 2018;315(3):G408–G419. doi:10.1152/ajpgi.00078.2018.
   PubMed Web of Science ®Google Scholar
• Olson JK, Rager TM, Navarro JB, Mashburn-Warren L, Goodman SD, Besner GE. Harvesting the benefits of biofilms: A novel probiotic delivery system for the prevention of necrotizing enterocolitis. J Pediatr Surg. 2016;51(6):936–941. doi:10.1016/j.jpedsurg.2016.02.062.
   PubMed Web of Science ®Google Scholar
• Julia V, McSorley SS, Malherbe L, Breittmayer J-P, Girard-Pipau F, Beck A, Glaichenhaus N. Priming by microbial antigens from the intestinal flora determines the ability of CD4+ T cells to rapidly secrete IL-4 in BALB/c mice infected with leishmania major. J Immunol. 2000;165(10):5637–5645. doi:10.4049/jimmunol.165.10.5637.
   PubMed Web of Science ®Google Scholar
• Chen X, Katchar K, Goldsmith JD, Nanthakumar N, Cheknis A, Gerding DN, Kelly CP. A mouse model of clostridium difficile-associated disease. Gastroenterology. 2008;135(6):1984–1992. doi:10.1053/j.gastro.2008.09.002.
   PubMed Web of Science ®Google Scholar
• D’Ostroph AR, So TY. Treatment of pediatric. Infect Drug Resist. 2017;10:365–375. doi:10.2147/IDR.S119571.
   PubMed Web of Science ®Google Scholar
• Hall BR, Armijo PR, Leinicke JA, Langenfeld SJ, Oleynikov D. Prolonged non-operative management of clostridium difficile colitis is associated with increased mortality, complications, and cost. Am J Surg. 2019;217(6):1042–1046. doi:10.1016/j.amjsurg.2019.01.017.
   PubMed Web of Science ®Google Scholar
• Hall JF, Berger D. Outcome of colectomy for clostridium difficile colitis: a plea for early surgical management. Am J Surg. 2008;196(3):384–388. doi:10.1016/j.amjsurg.2007.11.017.
   PubMed Web of Science ®Google Scholar
• Valdés-Varela L, Gueimonde M, Ruas-Madiedo P. Probiotics for prevention and treatment of clostridium difficile infection. Adv Exp Med Biol. 2018;1050:161–176.
   PubMed Web of Science ®Google Scholar
• Dinleyici M, Vandenplas Y. Clostridium difficile Colitis Prevention and Treatment. Adv Exp Med Biol. 2019;1125:139–146.
   PubMed Web of Science ®Google Scholar
• Spinler JK, Auchtung J, Brown A, Boonma P, Oezguen N, Ross CL, Luna RA, Runge J, Versalovic J, Peniche A, et al. Next-generation probiotics targeting clostridium difficile through precursor-directed antimicrobial biosynthesis. Infect Immun. 2017;85(10):10. doi:10.1128/IAI.00303-17.
   Web of Science ®Google Scholar
• Guo Q, Goldenberg JZ, Humphrey C, El Dib R, Johnston BC. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4:CD004827.
   PubMedGoogle Scholar
• Goldenberg JZ, Mertz D, Johnston BC. Probiotics to prevent clostridium difficile infection in patients receiving antibiotics. JAMA. 2018;320(5):499–500. doi:10.1001/jama.2018.9064.
   PubMed Web of Science ®Google Scholar
• Johnson S, Maziade PJ, McFarland LV, Trick W, Donskey C, Currie B, Low DE, Goldstein EJC. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis. 2012;16(11):e786–792. doi:10.1016/j.ijid.2012.06.005.
   PubMed Web of Science ®Google Scholar
• Goldstein EJC, Johnson SJ, Maziade PJ, Evans CT, Sniffen JC, Millette M, McFarland LV. Probiotics and prevention of clostridium difficile infection. Anaerobe. 2017;45:114–119. doi:10.1016/j.anaerobe.2016.12.007.
   PubMed Web of Science ®Google Scholar
• Goldenberg JZ, Yap C, Lytvyn L, Lo CK, Beardsley J, Mertz D, Johnston BC. Probiotics for the prevention of clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12:CD006095.
   PubMed Web of Science ®Google Scholar
• Johnston BC, Lytvyn L, Lo CK, Allen SJ, Wang D, Szajewska H, Miller M, Ehrhardt S, Sampalis J, Duman DG, et al. Microbial preparations (Probiotics) for the prevention of clostridium difficile infection in adults and children: an individual patient data meta-analysis of 6,851 participants. Infect Control Hosp Epidemiol. 2018;39(7):771–781. doi:10.1017/ice.2018.84.
   PubMed Web of Science ®Google Scholar
• Reuter G. The Lactobacillus and Bifidobacterium microflora of the human intestine: composition and succession. Curr Issues Intest Microbiol. 2001;2:43–53.
   PubMedGoogle Scholar
• Urbańska M, Szajewska H. The efficacy of Lactobacillus reuteri DSM 17938 in infants and children: a review of the current evidence. Eur J Pediatr. 2014;173(10):1327–1337. doi:10.1007/s00431-014-2328-0.
   PubMed Web of Science ®Google Scholar
• Spinler JK, Sontakke A, Hollister EB, Venable SF, Oh PL, Balderas MA, Saulnier DMA, Mistretta T-A, Devaraj S, Walter J, et al. From prediction to function using evolutionary genomics: human-specific ecotypes of Lactobacillus reuteri have diverse probiotic functions. Genome Biol Evol. 2014;6(7):1772–1789. doi:10.1093/gbe/evu137.
   PubMed Web of Science ®Google Scholar
• Spinler JK, Taweechotipatr M, Rognerud CL, Ou CN, Tumwasorn S, Versalovic J. Human-derived probiotic Lactobacillus reuteri demonstrate antimicrobial activities targeting diverse enteric bacterial pathogens. Anaerobe. 2008;14(3):166–171. doi:10.1016/j.anaerobe.2008.02.001.
   PubMed Web of Science ®Google Scholar
• Rao K, Young VB. Probiotics for prevention of clostridium difficile infection in hospitalized patients: is the jury still out? Gastroenterology. 2017;152(8):1817–1819. doi:10.1053/j.gastro.2017.04.027.
   PubMed Web of Science ®Google Scholar